Puma Biotechnology, Inc. (PBYI)
| Market Cap | 239.11M |
| Revenue (ttm) | 235.64M |
| Net Income (ttm) | 21.59M |
| Shares Out | 48.21M |
| EPS (ttm) | 0.45 |
| PE Ratio | 11.09 |
| Forward PE | 22.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 194,313 |
| Open | 4.920 |
| Previous Close | 4.990 |
| Day's Range | 4.900 - 5.080 |
| 52-Week Range | 2.130 - 7.730 |
| Beta | 1.31 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+41.13%) |
| Earnings Date | May 2, 2024 |
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breas... [Read more]
Financial Performance
In 2023, PBYI's revenue was $235.64 million, an increase of 3.34% compared to the previous year's $228.03 million. Earnings were $21.59 million, an increase of 1079450.00%.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PBYI stock is "Strong Buy" and the 12-month stock price forecast is $7.0.
News
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue it's 1Q-2024 results after the close on May 2, 2024, and host a conference call to discuss results at 1:30 p.m. PDT.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported an inducement award granted to one new hire in March 2024, as required under Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
LOS ANGELES--(BUSINESS WIRE)--The FDA cleared Puma Biotechnology's IND for Alisertib in HER2-negative, hormone receptor-positive metastatic breast cancer.
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released it's fourth quarter and full year 2023 earnings and will host a conference call to discuss operating results and outlook.
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO and President Alan Auerbach will participate in a Breast & Lung Cancer panel on 3/6/24 at TD Cowen's Health Care Conference .
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on Feb. 29 to discuss its fourth quarter and full year 2023 earnings results.
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that it had initiated ALISCA-Lung1, a Phase II clinical trial of alisertib in small cell lung cancer.
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present an update on Puma Biotechnology at the B. Riley Oncology Conf. on Jan. 18, 2024.
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the design of the Phase 2 alisertib trial for treatment of HER2-, HR+ metastatic breast cancer (PUMA-ALI-1201).
Puma Biotechnology Reports Third Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its Q3-2023 earnings release on Nov. 2, 2023, and hosted a conference call to discuss the results of the quarter.
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Nov. 2, 2023, following the release of its 3Q-2023 results.
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported findings from a Phase I/II study of Alisertib and pembrolizumab for Rb-Deficient HNSCC at the 2023 AACR-NCI-EORTC meeting.
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--The FDA has granted Orphan Drug Designation to Puma Biotechnology's drug candidate alisertib for the treatment of small cell lung cancer.
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO of Puma Biotechnology, will present a corporate update at the H.C. Wainwright Global Investment Conference beginning on 9/11/23.
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma has been notified by the FDA that its IND has been reviewed, and Puma can proceed with clinical development of alisertib monotherapy for SCLC.
Puma Biotechnology Reports Second Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 2Q'23 earnings release on Aug. 3 and hosted a call at 4:30 pm ET to discuss results.
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue operating results for 2Q-2023 on Aug. 3 and follow with a conference call at 1:30 pm PT.
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Biomarker findings from a P II study of alisertib+paclitaxel v. paclitaxel alone in met. HR+ and triple neg breast cancer were presented at ASCO 2023.
Puma Biotechnology Reports First Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--On May 4, Puma Biotechnology reported its earnings results for the quarter ended March 31, 2023.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its financial results for the first quarter of 2023 after market close, followed by a conference call, on May 4, 2023.
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
LOS ANGELES--(BUSINESS WIRE)--Results of Puma's Phase II TBCRC041 trial of alisertib in patients with endocrine-resistant advanced breast cancer published online in JAMA Oncology.
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
LOS ANGELES--(BUSINESS WIRE)--On March 2, 2023, Puma Biotechnology issued its financial results for the fourth quarter and full year ended Dec. 31, 2022.
Puma Biotechnology to Participate in a Panel Discussion at Cowen's 43rd Annual Health Care Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, w...
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 2, 2023, following the...
Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in On...